Jonathan
Martinelli
ab,
Rogelio
Jiménez-Juárez
ac,
Diego
Alberti
d,
Simonetta
Geninatti Crich
d and
Kristina
Djanashvili
*a
aDepartment of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands. E-mail: k.djanashvili@tudelft.nl
bDepartment of Science and Technological Innovation, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy
cDepartment of Organic Chemistry, National School of Biological Sciences, National Polytechnical Institute, Prolongación de Carpio y Plan de Ayala S/N, 11340, Mexico D.F., Mexico
dDepartment of Molecular Biotechnology and Health Sciences, University of Torino, via Nizza 52, 10126 Torino, Italy
First published on 21st September 2020
Paramagnetic macrocycles functionalized with phenylboronic moieties have proven to be interesting for MRI applications based on their ability to recognize cancer cells and generate local contrast. However, full use of the potential of this class of compounds is hampered by laborious and inefficient synthetic and, especially, purification procedures. The amphiphilic character of water-soluble phenylboronates renders them difficult compounds to be prepared through conventional solution synthesis due to the tendency to aggregate and form adducts with other nucleophiles. The new strategy described herein exploits the advantage of solid-phase synthesis with the application of DEAM-PS resin for anchorage and the subsequent simplified derivatization of boronates. GdDOTA-EN-PBA and its fluorinated analogue GdDOTA-EN-F2PBA were synthesized in a much easier, faster and economically convenient way to achieve good yields and purity. Furthermore, the effect of electron-withdrawing fluorine atoms on the aromatic ring of the latter compound was investigated by comparing the physico-chemical properties of both compounds as well as their binding affinity towards melanoma cancer cells.
Another interesting biomedical application of boron-based compounds lies in their capability for molecular recognition in the design of targeting contrast agents. In particular, phenylboronic acid (PBA) and its derivatives have shown the ability to strongly bind sialic acid, a nine-carbon monosaccharide unit that is overexpressed as the terminal group of glycolipids and glycoproteins on the surface of tumour cells.8 The mechanism of such interaction is based on the reversible formation of five- and six-membered cyclic boronate esters between the boronic group of PBA and the exocyclic polyol chain of sialic acid.9 This property of PBAs has been exploited in the preparation of several diagnostic and/or therapeutic targeting agents,10–12 the most successful of them being GdDOTA-EN-PBA (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, EN = ethylenediamine). Such a Gd(III)-complex bears a PBA moiety conjugated to a ligand (DOTA) through an aminoethylamide linker (EN) (Scheme 1). GdDOTA-EN-PBA has proved to be successful as a magnetic resonance imaging (MRI) contrast agent for in vivo tumour targeting based on the recognition of overexpressed sialic acid.13 In this case, a two-site cooperative binding mechanism is involved: in addition to the previously mentioned formation of cyclic boronates between PBA and the diol of the substrate, the recognition is enhanced by an electrostatic interaction involving the negatively charged carboxylate on the sialic acid residue and the positively charged amino group of the linker between the macrocycle and PBA. The same strategy was applied later with the radioactive Ga-68 complex of DOTA-EN-PBA enabling visualization of tumours by positron emission tomography (PET).11,14 Additionally, Yamamoto et al. have demonstrated the potential of a PBA-containing GdDTPA-based MRI contrast agent (DTPA = diethylenetriaminepentaacetic acid) for simultaneous neutron capture therapy, thus widening the medical applications of such systems.15
![]() | ||
Scheme 1 Solid-phase synthesis of DOTA-EN-PBA and DOTA-EN-F2PBA. (i) THF, rt, 2 h; (ii) THF, rt, 3 h; (iii) NaBH4, THF, rt, 4 h; and (iv) 1![]() ![]() |
Unfortunately, the amphiphilic character of boronates translates into severe difficulties in their preparation and purification, including solubility problems and the inclination to form oligomers or react with alcohols, amines, carboxylates and other nucleophilic species. Also, the pH-dependent equilibrium between a boronic acid and its boronate form represents an additional source of synthetic obstacles.16 For instance, the conventional synthesis of DOTA-EN-PBA was heavily affected in terms of the final yield and the time and effort required to purify the ligand.10 As an example of tedious procedures needed for the purification of PBA derivatives, time-consuming ion-exchange chromatography was also responsible for partial loss of the product.
In order to prevent the boronic acid moiety from affecting the efficacy of the various synthetic steps and the purification of the intermediate products, the boronate can be “protected” by binding it to a solid support. This would also allow the exploitation of the well-known advantages of solid-phase synthesis, such as the easy removal of excess reagents and by-products through simple filtration and washing. A few cases have been already described where conventional solid-phase peptide synthesis was exploited to build molecular parts of contrast agents.17–20 Several solid supports are reported in the literature to specifically bind boronic acids, including citronellic acid attached to Rink's amide resin, polystyrene derivatised with 2-methyl-2-(hydroxymethyl)-1,3-propanediol,21 catechol pendant polystyrene polymer,22 and more recently, 1-glycerol Merrifield resin.23 Among these, polystyrene functionalized with diethanolamine groups (DEAM-PS resin) seems to be endowed with more effective binding properties, and requires mild conditions to release the boronic acids after their derivatization.24–26
Herein, we report a new way to prepare DOTA-EN-PBA derivatives based on solid-phase synthesis. We were also interested in investigating the effect of the increased acidity of the boronate moiety on the binding to sialic acid. Therefore, an additional fluorinated ligand (DOTA-EN-F2PBA) was synthesised via the same successful procedure. Such a strategy allowed both compounds to be obtained in a more straightforward way and with higher yields compared to those reported previously for DOTA-EN-PBA. Gd(III)-complexes of both species were then prepared and their relaxometric properties were determined through standard procedures. Finally, the targeting ability of novel GdDOTA-EN-F2PBA towards sialic acid was studied on suitable cell cultures and compared to that of GdDOTA-EN-PBA.
After swelling the DEAM-PS resin in dry tetrahydrofuran for 30 min, 3-formylphenylboronic acid (1a) dissolved in anhydrous THF was first immobilized onto the resin (2a) by agitation in a filter syringe fixed onto an orbital shaker (50 rpm) for 2 hours at room temperature. This step was followed by reductive amination under analogous conditions (anhydrous THF, ambient temperature) between the aldehyde moiety and the primary amine of DOTA(OtBu)3-EN to form the anchored and protected precursor (3a) of the aimed ligand. This was obtained in one step by shaking the functionalized resin in dichloromethane and trifluoroacetic acid to achieve deprotection of the carboxylates and cleavage from the resin at the same time.
The yield calculated (as the trifluoroacetate form) with respect to DOTA(OtBu)3-EN was 62%, which definitely represents an improvement when compared to that reported in the literature for the synthesis in solution (33%).11 Following this protocol, all the solubility problems typical of PBA derivatives were avoided. The identity of DOTA-EN-PBA was confirmed by ESI mass spectrometry and full NMR characterization (see the ESI†) by comparison with the data previously reported.11 It is noteworthy that the main species observable in the mass spectrum of the ligand were the mono- and bis-dehydrated forms (Fig. S3 and S4†). By recording mass spectra at different values of cone voltage, these have been proved to be the consequence of fragmentation happening in the spectrometer and not of degradation prior to analysis; by decreasing the ionization voltage, the bis-dehydrated form progressively disappears while the mono-hydrated species increases (Fig. S4†).
Prompted by the positive outcome, the novel procedure was exploited to prepare a derivative of DOTA-EN-PBA bearing two electron-withdrawing fluorine atoms on the aromatic ring. Such a modification is expected to increase the acidity of the boronic acid,16 thus strengthening the binding to the sialic acid residues on the targeted tumour cells. Preliminarily, the effect of the F–atoms in different positions on the acidity of the boronic acid was tested by 11B NMR titration measurements (see the ESI†) on four commercial model compounds: one resembling the position of DOTA-EN-PBA (namely, 3-methylphenylboronic acid) and three bearing the halogens and the B(OH)2 groups in various sites of the aromatic ring (2,3-difluoro-4-methylphenylboronic acid [2,3-F-4-Me-PBA], 2,4-difluoro-5-methylphenylboronic acid [2,4-F-5-Me-PBA], 2,6-difluoro-5-methylphenylboronic acid [2,6-F-5-Me-PBA]). The measurements (Fig. S1†) revealed a pKa value of 7.2 for 2,3-F-4-Me-PBA, compared to 8.8 for 3-Me-PBA, 8.6 for 2,6-F-5-Me-PBA and 8.0 for 2,4-F-5-Me-PBA. Expecting an analogous two-orders-of-magnitude increase in pKa, a novel ligand (DOTA-EN-F2PBA) was designed with two fluorine atoms in the ortho- and meta-positions with respect to the attachment site of the pendant arm, while the boronic moiety was switched to the para-position. This would also allow the testing of the importance of the formation of the cyclic boronate in the recognition mechanism regardless of the additional contribution of the amine-carboxylate electrostatic interaction mentioned previously.
An analogous synthetic pathway was followed starting from 2,3-difluoro-4-formylphenylboronic acid (1b), which was first immobilized onto the DEAM-PS resin (2b), then conjugated to DOTA(OtBu)3-EN (3b) and finally deprotected/cleaved. The newly formed DOTA-EN-F2PBA ligand (trifluoroacetate form) was obtained in 52% yield and fully characterized by ESI MS and NMR spectroscopy (Fig. S2 and S8–S11†). The water solubility of DOTA-EN-PBA and DOTA-EN-F2PBA represents an important extension with respect to the compounds prepared by Gravel et al. via solid-phase synthesis on the DEAM-PS resin, especially when the amphiphilic behaviour of boronates is considered.
In order to prove the effectiveness of such a protocol, the literature procedure for the preparation of DOTA-EN-PBA was applied to prepare DOTA-EN-F2PBA without a solid-phase synthetic strategy (see the Synthetic procedures section). In this case, the product was achieved in 24% yield, less than half compared to the new procedure.
Besides the final yield, another advantage of the resin-binding approach is clear when the purity of the compound after the deprotection step is considered: the 19F NMR spectrum of DOTA-EN-F2PBA prepared in solution (Fig. 1 and S12†) revealed the coexistence of two species bearing a fluorinated arene, which could not be observed by 1H, 13C and 11B NMR spectroscopy. In particular, in addition to the two double doublets at −132 and −142 ppm from the expected product, two multiplets were also detected at −138 and −141 ppm, which furthermore gave cross-peaks in the 19F NMR COSY spectrum of the liquid-synthesis product (Fig. S13†). In contrast, this was not the case for DOTA-EN-F2PBA prepared through the novel procedure, whose 19F NMR spectrum shows only one set of signals (Fig. 1 and S11†). The presence of contaminants in the commercial reactant (2,3-difluoro-4-formylphenylboronic acid) was excluded by checking its NMR spectra.
Since the 11B NMR spectrum of the ligand prepared in solution only reports one resonance from the boronic moiety of the ligand (as compared to the solid-phase synthesis product) without additional signals from side-products (Fig. 2), it was concluded that the extra emerged species is the result of protodeboronation typical of phenylboronic acids with a fluorine in the ortho-position, as reported by Cox et al.27
![]() | ||
Fig. 2 Comparison between the 11B NMR spectra of DOTA-EN-F2PBA prepared on the solid support (top) and in solution (bottom). |
The presence of such a by-product was confirmed by both positive and negative ESI MS (Fig. S3†). The cleaner output further emphasizes the benefits of our novel solid-phase synthesis for the preparation of this kind of ligand: should such a side-reaction take place, the by-product would be released from the solid support and eliminated through successive washings.
![]() | ||
Fig. 3 1H NMRD profiles acquired at pH 7 and 25 or 37 °C for aqueous solutions of GdDOTA-EN-PBA (top) and GdDOTA-EN-F2PBA (bottom). |
The NMRD profiles measured for the two complexes at 25 °C and 37 °C were analysed using the conventional Solomon–Bloembergen–Morgan theory,29 leading to the determination of a set of characteristic parameters, such as the rotational correlation time (τR) and the exchange time (τM) of water coordinated to the metal centre with the bulk (Table 1). The longitudinal relaxivity values (r1p), representing the proton relaxation rate enhancement per 1 mM Gd(III) ion, were determined at 25 °C and 20 MHz to be 6.24 and 5.80 mM−1 s−1 for GdDOTA-EN-PBA and GdDOTA-EN-F2PBA, respectively. These values, slightly higher than those of typical monomeric GdDOTA complexes, can be attributed to the bigger molecular size due to the additional PBA pendant arm, which results in slower tumbling times as compared to GdDOTA (τR = 90 ps).30 The increased relaxivity values are expected to translate into an enhanced MRI contrast effect.
Parameter | GdDOTA-EN-PBA | GdDOTA-EN-F2PBA |
---|---|---|
a The following parameters were fixed to common values during the fitting procedure: rGd-H = 3.0 Å, D = 2.24 × 10−5 cm2 s−1, q = 1, a = 4.0 Å. | ||
20 MHz r 1p [mM−1 s−1] | 6.24 ± 0.21 | 5.80 ± 0.35 |
τ M [ns] | 69 ± 19 | 100 ± 23 |
τ R [ps] | 115 ± 5 | 112 ± 6 |
τ v [ps] | 36 ± 5 | 40 ± 7 |
Δ2 [1019 s−2] | 1.48 ± 0.35 | 1.14 ± 0.36 |
As expected, the values for the two complexes are similar, as there is no particular difference of relaxometric interest in their molecular structures. The slightly lower relaxivity of the fluorinated analogue suggests the influence of the rather remote aromatic group on the first coordination sphere of the complex, whereby a relative decrease in hydrophilicity induced by the fluorine atoms affects the water exchange rate at the Gd(III) ion (100 vs. 69 ns) and consequently the r1p value.
![]() | ||
Fig. 4 Evaluation of the bound Gd(III)-complexes upon incubation with melanoma cells: B16-F10 cells, 4 h of incubation in EBSS buffer w/o glucose at a Gd concentration of 0.6 mM. |
This seems to suggest that the advantageous effect of the electronegative substituents on increasing the acidity of the boronic group was counterbalanced by the shift of the latter from the meta-position in GdDOTA-EN-PBA to the para-position in the fluorinated derivative. As previously mentioned, because the amino group of DOTA-EN-PBA at physiological pH facilitates the recognition and binding to sialic acid residues by electrostatic interaction with the carboxylate of the glycan chain, when moving from a meta- to a para-substituted boronic acid, this interaction can be much less effective or even missed completely, thus weakening the targeting ability of the system. The similar results obtained for GdDOTA-EN-PBA and GdDOTA-EN-F2PBA indicate that the contribution of the electrostatic interaction is basically comparable to the enhanced binding strength achieved by increasing the PBA acidity. This confirms therefore that, as we aimed to prove, playing with the acidity of the vector, e.g. by introducing electron-withdrawing groups on the aromatic ring, is a good strategy to improve the targeting abilities of this type of ligand.
DOTA-EN-PBA: 62% yield (calculated as the trifluoroacetate form with respect to DOTA(OtBu)3-EN). The NMR characterization is in agreement with that reported in the literature (Fig. S3†).11
1H NMR (400 MHz, 25 °C, D2O): 7.75 (m, 2H), 7.48 (m, 2H), 4.24 (s, 2H), 3.7–3.3 (bm, 8H), 3.3–2.5 (bm, 20H). 13C NMR (100 MHz, 25 °C, D2O): 178.4, 173.0, 169.7, 151.5, 146.9, 129.7, 128.9, 126.8, 123.9, 61.3, 57.1, 56.4, 56.0, 52.0, 50.4, 48.7, 48.3, 46.7, 43.9, 35.6, 20.6. 11B NMR (128 MHz, 25 °C, D2O): −19.2 (bs). HR MS (ESI): [M − H2O + H]+m/z calculated for C25H40BN6O8 563.2995, observed 563.2989.
DOTA-EN-F2PBA: 52% yield (calculated as the trifluoroacetate form with respect to DOTA(OtBu)3-EN). 1H NMR (400 MHz, 25 °C, D2O[CD3CN]): 7.28 (m), 7.17 (m), 4.37 (bs), 3.81 (bm), 3.57 (m), 3.6–3.3 (bm), 3.39 (bm), 3.33 (bm), 3.23 (m), 3.2–2.8 (bm). 13C NMR (100 MHz, 25 °C, D2O[CD3CN]): 173–169 (CO), 155.3, 153.5, 151.3, 149.3, 131.3, 128.5, 61.3, 56–50, 34.9, 29.4, 20.7. 11B NMR (128 MHz, 25 °C, D2O[CD3CN]): 8.22 (bs). 19F NMR (376 MHz, 25 °C, D2O[CD3CN]): −131.79 (dd, 3JFF = 23.7 Hz, 4JFH = 4.5 Hz, C(F)CCH2), −141.54 (dd, 3JFF = 23.7 Hz, 4JFH = 3.0 Hz, C(F)C(B)). HR MS (ESI): [M − H2O + H]+m/z calculated for C25H38BF2N6O8 599.2807, observed 599.2803.
GdDOTA-EN-PBA: 96% yield. ESI+ MS: [M + H]+m/z calculated for C25H39BGdN6O9+ 736.2, observed 735.8.
GdDOTA-EN-F2PBA: 93% yield. ESI+ MS: [M + H]+m/z calculated for C25H37BF2GdN6O9+ 772.2, observed 771.8.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ob01552k |
This journal is © The Royal Society of Chemistry 2020 |